Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference44 articles.
1. Biomarkers of response to PD-1 pathway blockade;Li;Br. J. Cancer,2022
2. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody, Cancer;Stewart;Immunol. Res.,2015
3. Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers;Tarhini;Expert Opin. Biol. Ther.,2008
4. for the POSEIDON investigators, Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non–small-cell lung cancer: the phase III POSEIDON study;Johnson;J. Clin. Oncol.,2023
5. IMFINZI (durvalumab) prescribing information, 2022. https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/9496217c-08b3-432b-ab4f-538d795820bd/9496217c-08b3-432b-ab4f-538d795820bd_viewable_rendition__v.pdf. Accessed February 27, 2023.